论文部分内容阅读
背景与目的:体外及体内的临床研究显示,奥沙利铂(L-OHP)对多种肿瘤有显著抑制作用并与绝大多数抗癌药物具有相加或协同细胞毒作用。本文旨在观察L-OHP联合羟基喜树碱(HCPT)治疗晚期胃癌的近期疗效和患者耐受性,并与传统的化疗方案进行对比。方法:采用非随机的分组方法将43例晚期胃癌患者分为L-OHP+HCPT方案组(治疗组)与Vp-16+CF+5-FU(ELF)方案组(对照组),其中男性28例,女性15例,中位年龄59岁,KPS评分≥60,观察两组的近期疗效和患者耐受性。结果:治疗组24例有效率58.3%(14/24),对照组19例有效率42.1%(8/19)。治疗组有效率高于对照组,两组差异有显著性(P<0.05)。两组不良反应主要是骨髓抑制、恶心、呕吐、口腔炎、周围神经炎、静脉炎、脱发等,均在Ⅰ、Ⅱ度范围内。结论:L-OHP联合HCPT方案治疗晚期胃癌疗效较好,不良反应可以耐受。
Background and Objective: In vitro and in vivo clinical studies have shown that oxaliplatin (L-OHP) has a significant inhibitory effect on a variety of tumors and has additive or synergistic cytotoxic effects with most anticancer drugs. This article aims to observe the L-OHP combined with hydroxycamptothecin (HCPT) treatment of advanced gastric cancer and patient tolerance in the short term, and compared with the traditional chemotherapy. Methods: Forty-three patients with advanced gastric cancer were divided into the L-OHP + HCPT group (treatment group) and the Vp-16 + CF + 5-FU (ELF) Cases, 15 females, the median age of 59 years, KPS score ≥ 60, the two groups observed the short-term efficacy and patient tolerance. Results: The effective rate was 58.3% (14/24) in the treatment group and 42.1% (8/19) in the control group. The treatment group was more effective than the control group, the difference was significant (P <0.05). Two groups of adverse reactions are mainly bone marrow suppression, nausea, vomiting, stomatitis, peripheral neuritis, phlebitis, hair loss, etc., are in the I, II degree range. Conclusion: L-OHP combined with HCPT regimen has good curative effect on advanced gastric cancer and the adverse reaction can be tolerated.